Search
for

    GlossaryBenign Prostatic Hyperplasia (BPH)

    non-cancerous enlargement of the prostate gland common in older men

    Benign Prostatic Hyperplasia (BPH), also known as an enlarged prostate, is a non-cancerous increase in the size of the prostate gland. This condition is common in older men and can lead to urinary symptoms such as difficulty starting urination, a weak urine stream, and frequent urination, especially at night. BPH occurs due to hormonal changes and can be managed with medications, lifestyle changes, or surgical procedures if necessary.

    Related Terms

    Learn

    1 / 1 results

      learn Saw Palmetto

      a natural and far less effective alternative to Finasteride

    Research

    5 / 988 results

    Community Join

    5 / 123 results

      community No, Finasteride as a treatment for MPB was not an "accident"

      in Research/Science  105 upvotes 3 years ago
      Finasteride was intentionally developed to treat BPH and later approved for male pattern baldness (MPB) due to its 5AR inhibition effects. The delay in MPB approval was due to concerns about off-label use for female hirsutism and the prioritization of treating a more debilitating condition.

      community We need actual hair loss studies on Epristeride

      in Research/Science  6 upvotes 1 month ago
      Epristeride is a selective 5 alpha reductase type 2 inhibitor that may reduce scalp DHT similarly to finasteride, with potentially fewer side effects. It is suggested that combining epristeride with finasteride or dutasteride could enhance hair loss treatment effectiveness.
      FCE 28260: A Forgotten 5α-Reductase Inhibitor

      community FCE 28260: A Forgotten 5α-Reductase Inhibitor

      in Research  330 upvotes 3 months ago
      FCE 28260 (PNU 156765), an under-explored 5α-reductase inhibitor, showcases promising results in research by Giudici et al., outperforming well-known treatments like Finasteride in reducing the conversion of testosterone to DHT. Its superior efficacy, demonstrated through lower IC50 values in both natural and human recombinant enzyme studies, suggests it could offer more effective management of DHT-related conditions. Additionally, its lower molecular weight hints at better potential for topical application, potentially offering advantages in treating conditions such as androgenic alopecia. Despite its potential, it has not advanced in development, possibly due to financial limitations, leaving its therapeutic prospects and side effect profile largely unexplored.